Over the last few years, Mylan has enjoyed a cushy monopoly due to recall of their largest competitor. Consequently, the price of a life-saving pack of EpiPens has grown by 600% in the past several years, despite epinephrine being a relatively cheap substance. This price hike is unjust and potentially fatal for allergy sufferers with low income or no insurance. Address this problem publicly to introduce public pressure to end this greed.



